Thomas J Scriba Selected Research

MVA 85A

1/2019	A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
1/2018	Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
1/2017	Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.
1/2015	Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial.
3/2013	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
4/2012	A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.
6/2011	Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
1/2010	Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas J Scriba Research Topics

Disease

106	Tuberculosis (Tuberculoses) 05/2024 - 02/2008
50	Infections 03/2024 - 04/2006
7	Pulmonary Tuberculosis 01/2022 - 01/2018
4	Disease Progression 03/2024 - 01/2021
4	Inflammation (Inflammations) 08/2023 - 07/2017
4	Communicable Diseases (Infectious Diseases) 12/2019 - 05/2014
3	Human Influenza (Influenza) 08/2023 - 11/2005
3	Latent Infection 08/2023 - 12/2010
3	Coinfection 12/2021 - 02/2013
2	Pericarditis 08/2022 - 11/2011
2	Persistent Infection 01/2021 - 06/2017
2	Cryptococcal Meningitis 01/2017 - 01/2016
2	Necrosis 01/2015 - 01/2014
1	Constrictive Pericarditis 08/2022
1	Tuberculous Pericarditis 08/2022
1	Immune Reconstitution Inflammatory Syndrome 01/2022
1	Meningeal Tuberculosis (Tuberculous Meningitis) 01/2022
1	COVID-19 related pediatric multisystem inflammatory disease 01/2022
1	Virus Diseases (Viral Diseases) 12/2021
1	Seizures (Absence Seizure) 01/2021
1	Wasting Syndrome (Wasting Disease) 01/2019
1	Schistosomiasis (Bilharziasis) 01/2019
1	Lung Diseases (Lung Disease) 01/2018
1	Hematuria 01/2017

Drug/Important Bio-Agent (IBA)

49	VaccinesIBA 01/2024 - 11/2008
27	Biomarkers (Surrogate Marker)IBA 12/2022 - 05/2011
16	AntigensIBA 01/2023 - 04/2006
12	CytokinesIBA 08/2023 - 02/2008
10	GoldIBA 05/2022 - 03/2013
8	Interferon-gamma (Interferon, gamma)IBA 05/2022 - 07/2014
8	MVA 85AIBA 01/2019 - 01/2010
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2007
6	BCG Vaccine FDA Link 05/2023 - 04/2013
6	Tuberculosis VaccinesIBA 11/2022 - 01/2010
6	InterferonsIBA 12/2019 - 03/2015
5	Tuberculin (PPD)IBA 12/2021 - 01/2016
5	Interleukin-17 (Interleukin 17)IBA 01/2019 - 02/2008
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023 - 01/2019
4	LipidsIBA 10/2022 - 11/2015
4	Isoniazid (Ftivazide)FDA LinkGeneric 01/2022 - 11/2015
3	Messenger RNA (mRNA)IBA 01/2023 - 01/2019
3	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2016
3	HLA-DR Antigens (HLA-DR)IBA 01/2021 - 01/2021
2	SuperantigensIBA 08/2023 - 12/2007
2	Peptides (Polypeptides)IBA 01/2023 - 07/2007
2	Complement System Proteins (Complement)IBA 01/2023 - 11/2017
2	Interleukin-10 (Interleukin 10)IBA 01/2022 - 01/2016
2	ChemokinesIBA 01/2021 - 01/2015
2	AERAS-402IBA 01/2019 - 01/2017
2	ImmunosorbentsIBA 01/2018 - 07/2014
2	EnzymesIBA 01/2018 - 07/2014
2	EpitopesIBA 01/2017 - 07/2007
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017 - 07/2007
2	LigandsIBA 01/2017 - 02/2013
2	Interleukin-22 (IL-22)IBA 11/2011 - 02/2008
1	IceIBA 03/2024
1	phospholipase C epsilonIBA 03/2024
1	Type C PhospholipasesIBA 03/2024
1	Poly I-CIBA 08/2023
1	OxylipinsIBA 08/2023
1	Enterotoxins (Enterotoxin)IBA 08/2023
1	Transcription Factors (Transcription Factor)IBA 01/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2023
1	Adenosine Monophosphate (AMP)IBA 01/2023
1	GlucocorticoidsIBA 08/2022
1	tributyl phosphate (TBP)IBA 08/2022
1	Prednisolone (Predate)FDA LinkGeneric 08/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2022
1	Interleukin-27 (Interleukin 27)IBA 01/2022
1	Interleukin-12 (IL 12)IBA 01/2022
1	AerosolsIBA 01/2022
1	Interleukin-1 (Interleukin 1)IBA 01/2022
1	Volatile Organic CompoundsIBA 01/2022
1	SolutionsIBA 11/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Recombinant ProteinsIBA 01/2020
1	IntegrinsIBA 01/2020
1	Basic-Leucine Zipper Transcription FactorsIBA 01/2019
1	Interleukin-2 (IL2)IBA 01/2019
1	Subunit VaccinesIBA 12/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	Immunologic Factors (Immunomodulators)IBA 01/2018
1	Measles VaccineIBA 01/2018
1	AntibodiesIBA 01/2018
1	Immunoglobulin G (IgG)IBA 01/2018
1	sulfoglycolipidsIBA 01/2018
1	glucose mycolateIBA 01/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2017
1	IC31 adjuvantIBA 01/2017
1	insulin receptor-related receptor (IRR)IBA 01/2017
1	Protein Subunits (Protein Subunit)IBA 01/2017
1	NitritesIBA 01/2017
1	glucuronoxylomannanIBA 01/2016

Therapy/Procedure

17	Therapeutics 05/2024 - 01/2014
3	Art Therapy 01/2022 - 01/2019
3	Drug Therapy (Chemotherapy) 12/2017 - 01/2014
1	Immunotherapy 08/2022
1	Intravenous Administration 01/2020